ரேண்டால் கே News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from ரேண்டால் கே. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In ரேண்டால் கே Today - Breaking & Trending Today
Neurana Pharmaceuticals to Present at 21st Annual Pain Therapeutics Conference News provided by Share this article Share this article SAN DIEGO, May 11, 2021 /PRNewswire/ Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced that Randall Kaye, Chief Medical Officer, will present at the 21 st Annual Pain Therapeutics Conference. The conference takes place virtually May 10-11 th. Presentations will be available for registered attendees via the conference website. About Neurana Pharmaceuticals, Inc. Neurana Pharmaceuticals, Inc. is a privately held, clinical-stage, biotechnology company focused on the treatment of neuromuscular conditions, including acute, painful muscle spasms of the back. The company was founded in 2013 and is based in San Diego. Neurana s lead development compound is tolperisone, a novel, non-opioid, non-drowsy, non-cognitive impairing treatment, which the comp ....
Join SMi's 21st Annual Pain Therapeutics Virtual Conference in May 2021 – less than two weeks einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.
NervGen Pharma Corp.: NervGen Pharma Reports 2020 Year End Results Vancouver, British Columbia (Newsfile Corp. - April 8, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ( NervGen or the Company ), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financial results for the year ended December 31, 2020. Paul Brennan, NervGen s President & CEO, stated, We made substantial progress in the development of our lead program, NVG-291, towards clinical trials during 2020. We were able to resubmit our Investigational New Drug Application for NVG-291 early in 2021 and we look forward to starting our Phase 1 trial in Australia this quarter. We continue to generate encouraging preclinical data to support our programs to bring life-changing hope to many people suffering from nerve damage as a result of injury or neurodegenerative diseases. Pending successful completion of our ....